Cargando…

Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis

Objective: Administration of drugs targeting anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is often associated with serious immune-related adverse events (irAEs). Here, we performed a comprehensive analysis of organ-specific irAEs and treatment-related hematologic abnormalities and muscu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hang, Tan, Ping, Zheng, Xiaonan, Huang, Yu, Lin, Tianhai, Wei, Qiang, Ai, Jianzhong, Yang, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613615/ https://www.ncbi.nlm.nih.gov/pubmed/31308633 http://dx.doi.org/10.2147/DDDT.S196316

Ejemplares similares

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

The Association Between Metabolic Status and Risk of Cancer Among Patients With Obesity: Metabolically Healthy Obesity vs. Metabolically Unhealthy Obesity
por: Zheng, Xiaonan, et al.
Publicado: (2022)

Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy
por: Xu, Hang, et al.
Publicado: (2023)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Validation of the preoperative controlling nutritional status score as an independent predictor in a large Chinese cohort of patients with upper tract urothelial carcinoma
por: Xu, Hang, et al.
Publicado: (2018)

Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021)

LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients
por: Zheng, Xiaonan, et al.
Publicado: (2021)

Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: a propensity score-matched study
por: Lok, Waichan, et al.
Publicado: (2023)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration
por: Jacob, Saya L, et al.
Publicado: (2018)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives
por: Polepalli Ramesh, Balaji, et al.
Publicado: (2014)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Adverse Events Involving Hallux Metatarsophalangeal Joint Implants: Comprehensive Analysis of US Food and Drug Administration Data from 2010 to 2018
por: Akoh, Craig C., et al.
Publicado: (2020)

Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
por: Serebruany, Victor, et al.
Publicado: (2017)

S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors
Publicado: (1989)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
por: Xu, Hang, et al.
Publicado: (2019)

Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting
por: Serebruany, Victor L., et al.
Publicado: (2017)

A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19()
por: Patel, Purva, et al.
Publicado: (2023)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
por: Naganuma, Misa, et al.
Publicado: (2019)

A review of ocular adverse events of biological anti-TNF drugs
por: Nicolela Susanna, Fernanda, et al.
Publicado: (2020)

Automatic Extraction of Comprehensive Drug Safety Information from Adverse Drug Event Narratives in the Korea Adverse Event Reporting System Using Natural Language Processing Techniques
por: Kim, Siun, et al.
Publicado: (2023)

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine
por: Zheng, Xiaonan, et al.
Publicado: (2021)

Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)
por: Pera, Victor, et al.
Publicado: (2023)

Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
por: Shimada, Kazuyo, et al.
Publicado: (2019)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
por: Zhou, Zeyun, et al.
Publicado: (2020)

Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System
por: Chung, Soo Jie, et al.
Publicado: (2022)

Neurological adverse events following regional anesthesia administration
por: Kent, Christopher D, et al.
Publicado: (2010)

271 Evaluation of Adverse Events Associated to Administration of Omalizumab
por: Gomez, R. Maximiliano, et al.
Publicado: (2012)

A systematic review of adverse drug events associated with administration of common asthma medications in children
por: Leung, James S., et al.
Publicado: (2017)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2tuaej71esovrvou0nshnf4uie